🔎 Trials Near Me

Home › Leukemia › Pennsylvania

Pag-aaral pangklinika para sa Leukemia sa Pennsylvania

15 pag-aaral para sa Leukemia ang naghahanap ng mga kalahok sa mga site sa Pennsylvania.

Mga Lungsod sa Pennsylvania

Opisyal na teksto ng pag-aaral (English)

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • Spoknwrd Clinical Trials Inc., Easton
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06824168

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • University of Pennsylvania, Philadelphia
Nagre-recruitPhase 1/2
30 Days · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04065399

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

  • Research Site, Pittsburgh
Nagre-recruitPhase 3
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07509151

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Pennsylvania, Philadelphia
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitPhase 2
Edad 7 hanggang 25 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05082519

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Nagre-recruitObservasyonal na pag-aaral
Edad 60 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT03680677

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

  • Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitPhase 1
Edad 0 hanggang 29 · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07464951

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site 2, Pittsburgh
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 17, 2026 · NCT05475925

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT06131801

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Saint Christopher's Hospital for Children, Philadelphia
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 18, 2026 · NCT01790152

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

  • Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitPhase 1/2
1 Month – 25 Years · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT06839456

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Hospital of the University of Pennsylvania, Philadelphia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184

Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

  • Children's Hospital of Philadelphia, Philadelphia
Nagre-recruitMaagang Phase 1
Hanggang edad 30 · Lahat ng kasarian · Na-update Peb 20, 2026 · NCT02356653

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Philadelphia
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.